Skip to main content
Clinical Trials/DRKS00000043
DRKS00000043CompletedPhase 4

Assessment of the inflammation of oral mucosa in lymphoma patients receiving Palifermin after high-dose conditioning with BEAM and autologous peripheral blood stem cell transplantation

niversitätsklinikum Freiburg0 sites73 target enrollmentStarted: November 6, 2008Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
73

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to 75 Years (—)
Sex
All

Inclusion Criteria

  • primary high-grade lymphoma
  • > 2 risk factors according to IPI
  • refractory NHL/Hodgkin
  • all Burkitt's lymphoma (<30% bone marrow infiltration)
  • all chemotherapy sensitiv NHL- and Hodgkin-relapse
  • Life expectancy > 3 months

Exclusion Criteria

  • known CNS involvement
  • HIV disease or immunologic deficiency
  • severe concomitant disease
  • severe psychiatric illness
  • prior therapy with palifermin
  • hypersensitivity to one of the trial drugs
  • pregnancy, lactation, positive pregnancy test

Investigators

Similar Trials

Assessment of the inflammation of oral... | Clinical Trial